CVS wins upgrade to buy as analyst sees more upside potential than its peers

Dow Jones

14 Feb

MW CVS wins upgrade to buy as analyst sees more upside potential than its peers

By Steve Gelsi

Leerink boosts CVS to a 'buy' as the healthcare-company's stock stays hot.

CVS Health Corp.'s stock rose Thursday after the drugstore and healthcare-services company picked up an analyst upgrade on the heels of beating its quarterly profit expectations by a wide margin, and making strides in its pharmacy-benefit-manager business.

CVS stock $(CVS)$ was up 3.5%, on top of a 15% rise in the previous session after posting a stronger-than-expected fourth-quarter profit.

Leerink Partners analyst Michael Cherny raised his rating on CVS to buy from market perform and lifted his price target for the stock by $20 to $75 a share.

CVS is starting to benefit from stabilization in its Aetna health-insurance and pharmacy-benefits businesses, he said.

CVS's earnings projections are "likely driving more upside than downside" against Leerink's performance estimates for the company, he said.

"The stock remains at a discounted level versus historical ranges," Cherny said. "The peer set may offer growth-adjusted valuation that are also appealing, but for CVS, it is closer to the end of its issues than these peers."

Including Thursday's moves, CVS's stock is now up 45.7% in 2025, while the S&P 500 SPX has risen 3.4%.

-Steve Gelsi

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

February 13, 2025 12:05 ET (17:05 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2511786305"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2511786305\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2511786305?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-14 01:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2511786305","market":"other","top_or_hot":-1,"title":"CVS wins upgrade to buy as analyst sees more upside potential than its peers","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW CVS wins upgrade to buy as analyst sees more upside potential than its peers\n</p>\n<p>\n  By Steve Gelsi \n</p>\n<p>\n     Leerink boosts CVS to a 'buy' as the healthcare-company's stock stays hot. \n</p>\n<p>\n     CVS Health Corp.'s stock rose Thursday after the drugstore and healthcare-services company picked up an analyst upgrade on the heels of beating its quarterly profit expectations by a wide margin, and making strides in its pharmacy-benefit-manager business. \n</p>\n<p>\n     CVS stock <a href=\"https://laohu8.com/S/CVS\">$(CVS)$</a> was up 3.5%, on top of a 15% rise in the previous session after posting a stronger-than-expected fourth-quarter profit. \n</p>\n<p>\n     Leerink Partners analyst Michael Cherny raised his rating on CVS to buy from market perform and lifted his price target for the stock by $20 to $75 a share. \n</p>\n<p>\n     CVS is starting to benefit from stabilization in its Aetna health-insurance and pharmacy-benefits businesses, he said. \n</p>\n<p>\n     CVS's earnings projections are \"likely driving more upside than downside\" against Leerink's performance estimates for the company, he said. \n</p>\n<p>\n     \"The stock remains at a discounted level versus historical ranges,\" Cherny said. \"The peer set may offer growth-adjusted valuation that are also appealing, but for CVS, it is closer to the end of its issues than these peers.\" \n</p>\n<p>\n     Including Thursday's moves, CVS's stock is now up 45.7% in 2025, while the S&amp;P 500 SPX has risen 3.4%. \n</p>\n<p>\n     -Steve Gelsi \n</p>\n<p>\n     This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 13, 2025 12:05 ET (17:05 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CVS wins upgrade to buy as analyst sees more upside potential than its peers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCVS wins upgrade to buy as analyst sees more upside potential than its peers\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-02-14 01:05</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW CVS wins upgrade to buy as analyst sees more upside potential than its peers\n</p>\n<p>\n  By Steve Gelsi \n</p>\n<p>\n     Leerink boosts CVS to a 'buy' as the healthcare-company's stock stays hot. \n</p>\n<p>\n     CVS Health Corp.'s stock rose Thursday after the drugstore and healthcare-services company picked up an analyst upgrade on the heels of beating its quarterly profit expectations by a wide margin, and making strides in its pharmacy-benefit-manager business. \n</p>\n<p>\n     CVS stock <a href=\"https://laohu8.com/S/CVS\">$(CVS)$</a> was up 3.5%, on top of a 15% rise in the previous session after posting a stronger-than-expected fourth-quarter profit. \n</p>\n<p>\n     Leerink Partners analyst Michael Cherny raised his rating on CVS to buy from market perform and lifted his price target for the stock by $20 to $75 a share. \n</p>\n<p>\n     CVS is starting to benefit from stabilization in its Aetna health-insurance and pharmacy-benefits businesses, he said. \n</p>\n<p>\n     CVS's earnings projections are \"likely driving more upside than downside\" against Leerink's performance estimates for the company, he said. \n</p>\n<p>\n     \"The stock remains at a discounted level versus historical ranges,\" Cherny said. \"The peer set may offer growth-adjusted valuation that are also appealing, but for CVS, it is closer to the end of its issues than these peers.\" \n</p>\n<p>\n     Including Thursday's moves, CVS's stock is now up 45.7% in 2025, while the S&amp;P 500 SPX has risen 3.4%. \n</p>\n<p>\n     -Steve Gelsi \n</p>\n<p>\n     This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 13, 2025 12:05 ET (17:05 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CVS","symbol_name":"西维斯健康","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2511786305","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2511786305","pubTimestamp":1739466300,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Leerink boosts CVS to a 'buy' as the healthcare-company's stock stays hot.CVS Health Corp.'s stock rose Thursday after the drugstore and healthcare-services company picked up an analyst upgrade on the heels of beating its quarterly profit expectations by a wide margin, and making strides in its pharmacy-benefit-manager business.CVS stock  was up 3.5%, on top of a 15% rise in the previous session after posting a stronger-than-expected fourth-quarter profit.Leerink Partners analyst Michael Cherny raised his rating on CVS to buy from market perform and lifted his price target for the stock by $20 to $75 a share.CVS is starting to benefit from stabilization in its Aetna health-insurance and pharmacy-benefits businesses, he said.CVS's earnings projections are \"likely driving more upside than downside\" against Leerink's performance estimates for the company, he said.\"The stock remains at a discounted level versus historical ranges,\" Cherny said. \"The peer set may offer growth-adjusted valuat","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"CVS":"西维斯健康"},"translate_title":"分析师认为CVS比同行有更大的上涨潜力，因此获得买入评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CVS":1},"content_text":"MW CVS wins upgrade to buy as analyst sees more upside potential than its peers\n\n\n  By Steve Gelsi \n\n\n     Leerink boosts CVS to a 'buy' as the healthcare-company's stock stays hot. \n\n\n     CVS Health Corp.'s stock rose Thursday after the drugstore and healthcare-services company picked up an analyst upgrade on the heels of beating its quarterly profit expectations by a wide margin, and making strides in its pharmacy-benefit-manager business. \n\n\n     CVS stock $(CVS)$ was up 3.5%, on top of a 15% rise in the previous session after posting a stronger-than-expected fourth-quarter profit. \n\n\n     Leerink Partners analyst Michael Cherny raised his rating on CVS to buy from market perform and lifted his price target for the stock by $20 to $75 a share. \n\n\n     CVS is starting to benefit from stabilization in its Aetna health-insurance and pharmacy-benefits businesses, he said. \n\n\n     CVS's earnings projections are \"likely driving more upside than downside\" against Leerink's performance estimates for the company, he said. \n\n\n     \"The stock remains at a discounted level versus historical ranges,\" Cherny said. \"The peer set may offer growth-adjusted valuation that are also appealing, but for CVS, it is closer to the end of its issues than these peers.\" \n\n\n     Including Thursday's moves, CVS's stock is now up 45.7% in 2025, while the S&P 500 SPX has risen 3.4%. \n\n\n     -Steve Gelsi \n\n\n     This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 13, 2025 12:05 ET (17:05 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}